Table 1.
Clinicopathological characteristics and treatment outcomes
| Clinicopathological characteristics | No. of patients (%) | ||
|---|---|---|---|
| All patients; N = 52 | Sunitinib; N = 34 | Bevacizumab; N = 18 | |
| Median age | 52; range 29–70 | 52; range 30–69 | 52; range 29–70 |
| Post-menopausal | 30 (58%) | 20 (59%) | 10 (55%) |
| Pre-menopausal | 22 (42%) | 14 (41%) | 8 (45%) |
| Chinese | 34 (65%) | 23 (68%) | 11 (61%) |
| Malay | 10 (19%) | 5 (15%) | 5 (28%) |
| Indian | 3 (6%) | 3 (9%) | 0 (0%) |
| Others | 5 (10%) | 3 (9%) | 2 (11%) |
| TNBC | 12 (23%) | 8 (24%) | 4 (22%) |
| Non TNBC (HER2−/HR+) | 40 (77%) | 26 (76%) | 14 (78%) |
| Grade 1 | 2 (4%) | 2 (6%) | 0 (0%) |
| Grade 2 | 19 (36%) | 9 (26%) | 10 (55%) |
| Grade 3 | 31 (60%) | 23 (68%) | 8 (45%) |
| Clinical stage | |||
| Stage I | 1 (2%) | 0 (0%) | 1 (6%) |
| Stage II | 29 (55%) | 19 (56%) | 10 (55%) |
| Stage III | 17 (33%) | 10 (29%) | 7 (39%) |
| Stage IV | 5 (10%) | 5 (15%) | 0 (0%) |
| Non metastatic | 47 (90%) | 29 (85%) | 18 (100%) |
| Metastatic | 5 (10%) | 5 (15%) | 0 (0%) |
| Pathological response | |||
| Pathological complete response | 2 (4%) | 1 (3%) | 1 (6%) |
| Residual tumor present | 50 (96%) | 33 (97%) | 17 (94%) |
| Miller Payne histological response | |||
| Good | 29 (56%) | 18 (53%) | 11 (61%) |
| Poor | 15 (29%) | 11 (32%) | 4 (22%) |
| Unable to assessa | 8 (15%) | 5 (15%) | 3 (17%) |
| Clinical objective response on CT imaging by RECIST | |||
| Clinical CR/PR | 38 (73%) | 23 (67%) | 15 (83%) |
| Clinical stable disease | 12 (23%) | 9 (27%) | 3 (17%) |
| Primary progression of disease | 0 (0%) | 0 (0%) | 0 (0%) |
| No imaging for RECIST assessment done after treatment | 2 (4%) | 2 (6%) | 0 (0%) |
| Dead | 2 (4%) | 1 (3%) | 1 (6%) |
| Alive | 50 (96%) | 33 (97%) | 17 (94%) |
| Stage I–III patients who developed relapse | 4 (9%) | 3 (10%) | 1 (6%) |
| Stage I–III patients who remained disease free | 43 (91%) | 26 (90%) | 17 (94%) |
| Stage IV patients who developed progression of disease | 3 (60%) | 3 (60%) | 0 |
| Stage IV patients who remained progression free after mastectomy and radiotherapy | 2 (40%) | 2 (40%) | 0 |
CR/PR complete response/partial response; CT computed tomography; HER2− human epidermal growth factor receptor 2 negative; HR+ hormone receptor positive; IHC immunohistochemistry; RECIST response evaluation criteria in solid tumors
aMiller Payne score could not be assessed in patients if there was insufficient tissue after prior sectioning for IHC analysis or if the baseline tumor content was <5% in the baseline samples